Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||04/03/2019|
|Rapid review completed||22/05/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that risankizumab not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013|